CRISPR and Gene Editing: The Nobel-Winning Tool India Is Still Regulating
May 27, 20268 min read
The question reads: "Consider the following statements about CRISPR-Cas9 technology."
You know it is a gene-editing tool. You know it won the 2020 Nobel Prize in Chemistry for Emmanuelle Charpentier and Jennifer Doudna. But the question is not about the science. It is about the regulation. "Which of the following statements about the regulatory framework for genome-edited organisms in India is correct?"
Option A: All gene-edited organisms are regulated as genetically modified organisms (GMOs) under the Environment Protection Act 1986.
Option B: The 2022 MoEFCC notification exempts SDN-1 and SDN-2 genome edits from GM regulation.
Option C: India has approved commercial cultivation of gene-edited crops.
Option D: The Genetic Engineering Appraisal Committee (GEAC) is the sole authority for gene-edited food product approval.
The answer is Option B. In 2022, India exempted Site-Directed Nuclease (SDN-1 and SDN-2) genome edits - changes that do not introduce foreign DNA - from GM regulation. But SDN-3 edits (which insert foreign DNA) remain under GMO rules. And no gene-edited food crop has been approved for commercial cultivation yet.
[TOPIC CLASSIFICATION]
Topic type: Biotechnology + Regulatory Policy (intersection of scientific innovation and legal frameworks)
PYQ frequency: Moderate (2-3 questions in last 5 years on gene editing, mostly Prelims)
Primary GS paper: GS-3 (Science and Technology, Environment)
[EXAMINER REASONING]
Trap: Confusing mission objectives, launch vehicles, or technological capabilities. Examiners test precise technical terminology.
Most confused: The distinction between civilian and strategic (dual-use) technology, and between indigenous development vs licensed production vs import.
Key anchor: The institutional architecture (ISRO, DRDO, DAE, CSIR, ICMR, DBT, MeitY) and policy framework (Space Policy, Nuclear Doctrine, Biotechnology Guidelines, National AI Strategy, Drone Rules).
Current affairs hook: Major missions (Chandrayaan-3, Aditya-L1, Gaganyaan), new policy initiatives (IN-SPACe, iDEX, Semiconductor Mission, Quantum Mission, AI Mission), defence tests (Agni, S-400, ARIHANT), health tech (mRNA, vaccines).
Mains hinge: Frame answers around the core tension - self-reliance vs international cooperation, strategic autonomy vs technology access, security vs transparency, innovation vs regulation.
Core Concept
CRISPR-Cas9 is a gene-editing tool adapted from a bacterial immune system. Bacteria capture fragments of viral DNA and integrate them into their own genome as "spacers" between CRISPR repeats. When the same virus attacks, the bacteria transcribe CRISPR RNA that guides the Cas9 nuclease to cut the viral DNA at the precise location. Scientists repurposed this: design a guide RNA for any target DNA sequence, and Cas9 cuts it. The cell repairs the cut through one of two pathways:
Non-homologous end joining (NHEJ): Error-prone, introduces small insertions or deletions that disrupt the gene (SDN-1)
Homology-directed repair (HDR): Uses a repair template to make precise changes (SDN-2) or insert new genetic material (SDN-3)
India's regulatory journey: The 1989 Rules under EPA 1986 created a six-tier regulatory system for GMOs - from Institutional Biosafety Committees (IBSCs) to the GEAC at the top. Every GM crop must pass through: lab trials → contained field trials → open field trials → environmental release → commercial approval. No GM food crop has crossed the final hurdle in 20 years. Bt cotton (2002) is the only transgenic crop approved for cultivation.
The 2022 MoEFCC Office Memorandum changed the landscape. It exempted SDN-1 and SDN-2 genome-edited products from the 1989 Rules, provided they do not contain foreign DNA. These products would instead be regulated by the existing seed laws (Seed Act 1966, Protection of Plant Varieties and Farmers' Rights Act 2001) and the FSSAI for food safety. The DBT (Department of Biotechnology) guidelines on genome editing (2020) provide technical guidance for research.
The paradox: India has some of the world's best genome-editing researchers (particularly at IITs, ICAR institutes, and NIPGR), a regulatory exemption that is among the most progressive in the developing world, but no commercial gene-edited product on the market. The bottleneck is not science - it is the absence of a clear product-approval pathway under non-GM regulations.
Globally, the US (USDA) exempts SDN-1 edits from biotech regulation unless the plant is a plant pest. The EU, by contrast, ruled in 2018 that gene-edited organisms are GMOs and subject to the same stringent regulations. Japan and Australia have intermediate frameworks. India's SDN-1/SDN-2 exemption aligns with the US approach, but without the corresponding regulatory machinery to evaluate products.
Key Facts
2020 Nobel Prize in Chemistry: Emmanuelle Charpentier and Jennifer Doudna for CRISPR-Cas9
Three types of SDN edits: SDN-1 (gene knockout), SDN-2 (gene correction), SDN-3 (gene insertion)
India regulatory body: GEAC (Genetic Engineering Appraisal Committee), MoEFCC
2022 Office Memorandum: exempts SDN-1 and SDN-2 from GM Rules 1989
Genome-edited crops in advanced Indian trials: mustard (low glucosinolate), rice (drought tolerant), banana (longer shelf life)
Global regulatory spectrum: US (exempts SDN-1), EU (regulates as GMO), Japan (exempts with notification), Australia (exempts no-new-trait)
Human germline editing: banned in India under ICMR guidelines, but no specific legislation prohibits it
Patent landscape: CRISPR patents controlled by Broad Institute (US) and UC Berkeley, Indian research institutions face licensing constraints
Previous Year Questions
Year
Stage
What was tested
2024
Prelims
Difference between CRISPR and earlier gene-editing techniques
2023
Prelims
Application of CRISPR in agriculture and medicine
2022
Prelims
GEAC role and composition
2020
Prelims
SDN-1 and SDN-2 distinction
2019
Mains GS-3
"Gene editing is a double-edged sword." Discuss in the context of agricultural biotechnology.
2018
Prelims
GMO regulatory framework in India
Statement Elimination Guide
"CRISPR-Cas9 introduces foreign DNA into the organism's genome." False. CRISPR-Cas9 cuts the DNA at a specific site; the cell's repair mechanism introduces changes. SDN-1 and SDN-2 edits involve no foreign DNA insertion.
"Gene editing and genetic modification are regulated under the same framework in India." False. SDN-1 and SDN-2 gene edits (without foreign DNA) were exempted from GM Rules in 2022. They fall under seed laws and FSSAI.
"India has approved commercial cultivation of GM mustard." False. DMH-11 mustard has GEAC's recommendation for environmental release but is blocked by a Supreme Court stay order.
"The 2022 exemption for SDN-1 and SDN-2 edits was made through a parliamentary amendment to the EPA." False. It was an Office Memorandum from MoEFCC - executive action, not legislative - and can be reversed without going through Parliament.
"CRISPR-Cas9 was originally discovered as a gene-editing tool in mammals." False. It was discovered as a bacterial immune system. The gene-editing application was a repurposing of the natural mechanism.
Current Affairs Hook
The Department of Biotechnology launched the Genome Engineering Technologies Programme in 2024 with 200 crore outlay. It funds research on gene-edited crops for climate resilience - drought-tolerant rice, nitrogen-use-efficient wheat, and disease-resistant banana. Eight products are in the pre-commercial trial stage.
The Supreme Court's ongoing stay on GM mustard has created de facto policy paralysis. The 2024 parliamentary committee on agriculture recommended a time-bound approval pathway for gene-edited crops, separate from GM regulation. No legislative action has been taken.
India's genome-edited crop research focuses on traits that do not require foreign DNA - making them SDN-1/SDN-2 edits, eligible for the 2022 exemption. DT-Rice (drought-tolerant, developed by ICAR-NIPGR) uses SDN-1 to knock out a gene that suppresses stress response. It is expected to be the first gene-edited crop to seek commercial approval.
FSSAI has not issued final guidelines for food safety assessment of gene-edited products. The 2022 exemption creates a regulatory gap: who evaluates food safety for SDN-1/SDN-2 products if they are not GMOs? The Food Safety and Standards Act 2006 does not have a specific provision for gene-edited food.
Internationally, Japan approved gene-edited tomatoes (high GABA content for blood pressure reduction) and pufferfish in 2021 through a notification process - not a full food safety review. The US approved gene-edited soybeans (high oleic acid) and mushrooms (non-browning) through USDA exemption letters. India has no equivalent notification mechanism.
Interlinkages
Agriculture: Gene editing can develop climate-resilient crop varieties faster than conventional breeding (which takes 8-12 years for a new variety) and without the regulatory burden of GM (which has not approved a single food crop in 20 years). Drought-tolerant, flood-tolerant, salt-tolerant varieties are in development.
Ethics: Germline editing - changes to sperm, eggs, or embryos that are heritable - is banned in over 40 countries. The 2018 He Jiankui affair (CRISPR-edited twins in China) triggered global calls for a moratorium. India has no law against germline editing, only ICMR ethical guidelines.
IPR: CRISPR patents are among the most contested in modern biotechnology. The Broad Institute (US) holds patents for eukaryotic (plant/animal) applications; UC Berkeley holds the foundational patent. Indian institutions developing gene-edited crops must navigate this patent landscape or develop alternative editing systems (e.g., base editors, prime editors).
Environment: Gene-edited crops could reduce pesticide use (disease-resistant varieties) and fertiliser use (nitrogen-efficient varieties). The environmental release assessment for gene-edited crops is less stringent than GM because no new genetic combination is introduced - but the ecological impact of large-scale cultivation of edited crops is unknown.
International Relations: The EU's strict regulation of gene editing as GMO creates a trade barrier for Indian gene-edited products. Indian exports of GM-free status (soybean, maize, rice) could be affected if gene-edited varieties are commercially cultivated without segregation protocols.
Common Mistakes
Calling all gene-edited products "GMOs." If no foreign DNA is present (SDN-1, SDN-2), the product is not a GMO in the classical sense. India treats it separately. The EU does not.
Assuming that because a product is not a GMO, it has no regulatory oversight. SDN-1/SDN-2 products still require seed certification, variety release notification, and FSSAI evaluation for food safety. The regulatory pathway is lighter, not absent.
Confusing the regulatory status of gene editing in research vs. commercial release. Research on gene editing is governed by DBT guidelines (2020) and IBSC oversight. Commercial release requires additional approvals that do not yet have a clearly defined pathway.
Thinking gene editing replaces GM. Gene editing can do things GM cannot (precise endogenous gene modification) but cannot do things GM can (introduce genes from unrelated species). They are complementary tools.
Overlooking the off-target effect concern. CRISPR can cut at unintended sites in the genome. The science has improved significantly (guide RNA design tools, high-fidelity Cas9 variants), but off-target effects remain a regulatory concern, especially when the edit is heritable.
Revision Snapshot
CRISPR-Cas9 is a bacterial immune system repurposed for precise gene editing. It won the 2020 Nobel Prize. India's 2022 MoEFCC Office Memorandum exempts SDN-1 (gene knockout) and SDN-2 (gene correction) from GM regulation, provided no foreign DNA is inserted. SDN-3 edits (foreign DNA insertion) remain under the 1989 GM Rules. No gene-edited food crop has been commercialised in India, though several are in advanced trials (drought-tolerant rice, disease-resistant banana). The GEAC remains the apex body for GM regulation but has no defined role for SDN-1/SDN-2 products. Globally, regulation ranges from US-style exemption to EU-style GMO equivalence. The He Jiankui case (2018 CRISPR-edited human embryos) triggered a global moratorium on human germline editing. India lacks specific legislation on human germline modification, relying only on ICMR guidelines.
Source Notes
Department annual reports (Space, Atomic Energy, Defence R&D, Biotechnology, S&T)
ISRO, DRDO, DAE, CSIR, ICMR, DBT, MeitY official publications